Market-View-Feature-Image

View on market: Volatility Prevails, Market is searching for better value

Equities in the Asia-Pacific area surged higher, following the advances in the US market as investors braced for the Federal Reserve’s newest monetary policy announcement. As of 06:28 a.m., the S&P ASX 200 was trading 9.28 points, or 0.12% higher, at 7,712.5, while the KOSPI was trading 28.8 points, or 1.05% higher, at 2,684.6. The S&P 500 reached a fresh record high with the support of a surge in tech stocks in the United States. Nvidia Corp. increased as a result of predictions that its new chips will drive a surge that has already increased the company’s valuation by $1 trillion this year. As of Tuesday, the Nasdaq 100 and S&P 500 indexes had increased by 0.39% and 0.56%, respectively. In the meantime, the yield on the US 10-year bond was at 4.29%.

Economic Calendar:

  • USD : Initial Jobless Claims on 21st March, 2024
  • USD : Fed Interest Rate Decision on 20th March, 2024
  • INR : Nikkei Services PMI on 21st March, 2024
  • INR : Nikkei S&P Global Manufacturing PMI on 21st March, 2024

Brokerage Radar:

JEFFERIES ON LTMINDTREE: Buy, TP cut to Rs 5890; Resignation of LTIM’s CFO, alongside a slew of other senior-level exits, suggests that LTIM still faces integration issues. Given this, may take longer to realize rev synergies; Cut est. by 5-9% & expect 15% EPS CAGR in FY24-26

CLSA ON GAIL: Sell, TP Rs 165; Takeaways from Vijaipur site visit; Key pilot projects to supplement Gail’s sustainability goals; These initiatives, which include green hydrogen & captive solar power generation, underscore Co’s commitment for energy transition & to be net zero by 2040

International Markets:

U.S & Europe:

Particulars 19th March Chg. Chg.(%)
Nasdaq 16166.79 63.34 0.39
Dow 39110.76 320.33 0.83
FTSE 7738.30 15.75 0.20
CAC 8201.05 52.91 0.65
DAX 17987.49 54.81 0.30
Dow Fut.* 39524.00 -15.00 -0.04

Asian markets:

Particulars 20th March Chg. Chg.(%)
GIFT Nifty 21937.00 75.00 0.34
Nikkei 40003.60 263.16 0.66
Straits Times 3180.96 7.41 0.23
Hang Seng 16573.25 43.77 0.26
Shanghai 3061.54 -1.22 -0.04

ADR Watch:

Particulars 19th March  Chg.       Chg.(%)
Dr. Reddy 73.09 -2.40 -0.03
HDFC Bank 55.45 -0.56 -0.01
ICICI Bank 25.90 -0.05 0.00
Infosys 18.84 -0.32 -0.02
Wipro 5.94 -0.11 -0.02

Commodities & Currency:

Particulars Current Price Chg.(%)
USD/INR 83.01 -0.02
Brent 87.22 -0.18
Gold 2162.05 0.11
Silver 25.15 0.05

FIIs & DIIs:

Particulars 19th March 18th March
FIIs                          1421.48 -2051.09
DIIs 7449.48 2260.88

News Update:

Tata Consultancy Services: The U.S.-based Central Bank selected TCS BaNCS to update core technology infra.

UltraTech Cement: The composite scheme of arrangement between Kesoram Industries and UltraTech Cement has been successfully completed, marking a significant milestone for both companies.

Aditya Birla Capital: Promoter to exercise a green shoe option for shares of Aditya Birla Sun Life AMC.

GPT Healthcare: The company reported revenue of Rs 96.6 crore, up 4% YoY, and net profit of Rs 11.5 crore, up 37.4% YoY for Q3 FY24.

KIOCL: The company installed four vertical pressure filters in the pellet plant unit at Mangalore, with the capacity of each filter at 100 tn/hr.

Shakti Pumps: The board approved the QIP of up to Rs 200 crore at a floor price of Rs 1,272.09 per share.

Matrimony.com: The board approved the re-appointment of Murugavel Janakiraman as managing director for three years, effective April 1.

Care Ratings: The board approved the incorporation of a wholly owned subsidiary in GIFT City, Gujarat.

Patanjali Foods: The company issued clarification that the Supreme Court order relates to ads for ayurvedic products and medicines from Patanjali Ayurved and has no bearing on the company.

Rushil Decor: The company incorporated the unit Rushil Modala Ply for the manufacturing and sale of plywood and allied products.

Aurobindo Pharma: The company received USFDA approval for Mometasone Furoate Monohydrate nasal spray.

Apollo Hospital: The company redesignated Madhu Sasidhar as President and CEO, Hospitals Division, effective April 1.

Narayan Hrudayalaya: The company approved an allotment of 30,000 NCDs worth Rs 300 crore on a private placement basis.

NBCC: The company’s subsidiary, HSCC (India), has secured a Rs 14 crore work order for lab equipment procurement for the Himachal Pharma Testing Lab.

Persistent System: Acquired a 100% shareholding of Persistent Systems U.K. from Aepona Group.

Samvardhana Motherson International: Announced the acquisition of an 81% stake in the Yachiyo 4W business and 100% equity capital in Yachiyo India manufacturing.

Source: Moneycontrol, Bloomberg Quint, Investing 

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and

(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.

For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale.

Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

  1. Reports
  2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;

(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

  1. Compensation

(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;

(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;

(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(d) EWL  or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.